Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Assets (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Non-Current Assets for 10 consecutive years, with $212.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 71.11% to $212.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $212.7 million through Dec 2025, up 71.11% year-over-year, with the annual reading at $212.7 million for FY2025, 71.11% up from the prior year.
  • Non-Current Assets hit $212.7 million in Q4 2025 for Ascendis Pharma A, up from $124.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $212.7 million in Q4 2025 to a low of $123.8 million in Q4 2023.
  • Historically, Non-Current Assets has averaged $156.1 million across 5 years, with a median of $150.2 million in 2021.
  • Biggest five-year swings in Non-Current Assets: tumbled 47.43% in 2021 and later soared 71.11% in 2025.
  • Year by year, Non-Current Assets stood at $150.2 million in 2021, then grew by 12.92% to $169.6 million in 2022, then dropped by 27.02% to $123.8 million in 2023, then increased by 0.41% to $124.3 million in 2024, then soared by 71.11% to $212.7 million in 2025.
  • Business Quant data shows Non-Current Assets for ASND at $212.7 million in Q4 2025, $124.3 million in Q4 2024, and $123.8 million in Q4 2023.